Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Mol Ther. 2010 Jun;18(6):1224-32. doi: 10.1038/mt.2010.30. Epub 2010 Feb 23.
CD4(+) T cells contribute to the antitumor T-cell response as both effectors that promote tumor rejection and helpers that facilitate the activation of other antitumor effector cells, such as CD8(+) T cells. Maximal engagement of both effector and helper CD4(+) T-cell responses is a desirable attribute of cancer vaccines. We have employed the B16F10 murine melanoma model and a series of recombinant adenovirus (Ad) vaccines expressing mutant forms of the tumor antigen, dopachrome tautomerase, to investigate the relationship between antigen processing and the antitumor CD4(+) T-cell response. Our results have revealed an unexpected dichotomy in the generation of helper and effector CD4(+) T-cell responses where CD4(+) T effector responses are dependent upon protein processing and trafficking, whereas CD4(+) T helper responses are not. The results have important implications for strategies aimed at augmenting antigen immunogenicity by altering intracellular processing and localization.
CD4(+) T 细胞作为促进肿瘤排斥的效应物和促进其他抗肿瘤效应细胞(如 CD8(+) T 细胞)激活的辅助物,有助于抗肿瘤 T 细胞反应。癌症疫苗的理想特征是最大程度地发挥效应和辅助性 CD4(+) T 细胞反应。我们使用 B16F10 鼠黑色素瘤模型和一系列表达肿瘤抗原多巴色素互变异构酶突变体的重组腺病毒 (Ad) 疫苗来研究抗原加工与抗肿瘤 CD4(+) T 细胞反应之间的关系。我们的结果揭示了辅助性和效应性 CD4(+) T 细胞反应的生成中存在一种意想不到的二分法,其中 CD4(+) T 效应反应依赖于蛋白加工和转运,而 CD4(+) T 辅助反应则不依赖于蛋白加工和转运。这些结果对旨在通过改变细胞内加工和定位来增强抗原免疫原性的策略具有重要意义。